Gilead (GILD) to Acquire HOOK for $10 million

Gilead Sciences Inc. (NASDAQ:GILD) has announced it will be taking over HOOKIPA Pharma Inc. (NASDAQ:HOOK) for a consideration of $10 million.

Gilead Sciences Inc. (NASDAQ:GILD) commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. GILD is only purchasing HOOK’s antiviral programs, specifically the “HB-400” & “HB-500”. The company first invested $21.25 million in HOOK in 2023, with the aim of advancing its HIV program, i.e., through only the HB-500 program at that time.

Gilead Sciences Inc. (NASDAQ:GILD) has also backed a merger between HOOK and Poolberg Pharma, in an attempt to make a stronger clinical-stage biopharmaceutical company focused on next-generation immunotherapies for cancer and other serious diseases

HOOKIPA Pharma is a clinical-stage biopharmaceutical company that develops immunotherapies targeting infectious diseases based on its proprietary arenavirus platform. HOOK has a current market capitalization of over $19 million.

Regarding the terms and timelines of the financing, the agreement will take place in three milestones. The first $3m will be paid out at the close of the deal. After that, a three-phase transfer plan will make HOOK eligible to receive $7m. The first phase will give HOOK access to the first tranche of $3m, and the remaining two phases will see HOOK receive $2 million for each phase.

The deal is currently awaiting approval from the shareholders of HOOK. The company’s share price peaked at $1.75 on May 21, 2025, and closed at $1.52 at the end of trading.

While we acknowledge the potential of GILD, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GILD and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy

Disclosure: None.